kuhnert

Zum 1. Advent: Wein-Wurm Rudi und Winzerfiguren aus dem Erzgebirge

Bergmann, Engel und Nussknacker aus dem Erzgebirge werden vom heutigen 1. Advent an bis zu Hochneujahr wohl in fast keiner sächsischen Weihnachtsstube fehlen. Gerade bei Räuchermännchen sind aber längst mehr als nur die traditionellen Figuren zu finden, bestätigte der Verband Erzgebirgischer Kunsthandwerker und Spielzeughersteller. Fast alle Berufe seien zu haben. Kein Wunder, dass also auch Winzer in diesen Tagen in den erzgebirgischen Hutz´nstuben gemächlich vor sich hin nebeln.

Keep reading

5

Opening:

ARTIST SWEETHEARTS - Künstlerhaus Dortmund

25th April – 14th June


Michel Aniol + Meike Kuhnert (Berlin)
Pascal Aperdannier + Anne Paschvoß (Berlin)
Klaus Erich Dietl + Stephanie Müller (Munich)
Guda Koster + Frans van Tartwijk (Amsterdam)
Mandy Krebs + Marko Schiefelbein (Berlin)
Susanne Kutter + Markus Willeke (Berlin)
Torben Laib + Madeleine Christin Leroy (Kiel)
Katharina Maderthaner + Christian Schreckenberger (Düsseldorf)
Susanne Maurer + Marc Taschowsky (Berlin)
Kihyun Park + Florian Rosier (Leipzig)


photos © JS

A phase I study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma.

A phase I study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma.

Blood. 2015 Apr 17;

Authors: Rothe A, Sasse S, Topp MS, Eichenauer DA, Hummel H, Reiners KS, Dietlein M, Kuhnert G, Kessler J, Buerkle C, Ravic M, Knackmuss S, Marschner JP, Pogge von Strandmann E, Borchmann P, Engert A

Abstract
AFM13 is a bispecific, tetravalent chimeric antibody construct (TandA(®)) designed for the treatment of CD30-expressing malignancies. AFM13 recruits natural killer (NK) cells via binding to CD16A as immune effector cells. In this phase I dose escalation study 28 patients with heavily pre-treated relapsed or refractory Hodgkin lymphoma received AFM13 at doses of 0.01 to 7mg/kg body weight. Primary objectives were safety and tolerability. Secondary objectives included pharmacokinetics (PK), anti-tumor activity and pharmacodynamics (PD). Adverse events were generally mild to moderate. The maximum tolerated dose was not reached. PK assessment revealed a half-life of up to 19 hours. Three of 26 evaluable patients achieved partial remission (11.5%) and 13 patients achieved stable disease (50%) with an overall disease control rate of 61.5%. AFM13 was also active in brentuximab vedotin refractory patients. In 13 patients who received doses of ≥1.5mg/kg AFM13 the overall response rate was 23% and the disease control rate was 77%. AFM13 treatment resulted in a significant NK-cell activation and decrease of soluble CD30 in peripheral blood. In conclusion, AFM13 represents a well-tolerated, safe and active targeted immunotherapy of Hodgkin lymphoma. A phase II study is currently planned to optimize the dosing schedule in order to further improve the therapeutic efficacy. The phase I study is registered to http://ift.tt/PmpYKN as NCT01221571.

PMID: 25887777 [PubMed - as supplied by publisher]



via pubmed: lymphoma daily http://ift.tt/1HlRIsi